PBS listings for bone marrow and prostate treatment
The Gillard Government has announced a boost to the fight against life-threatening conditions with the listing of new drugs on the Pharmaceutical Benefits Scheme (PBS).
From 1 February, changes to the PBS will extend the lives of those suffering from some rare bone marrow disorders, and provide more support to men with prostate conditions.
Azacitidine, Powder for injection, 100mg, (Vidaza) will help extend the lives of over 670 Australians suffering from bone marrow disorders. Azacitidine is now listed on the PBS as a Section 100 Highly Specialised Drug for the treatment of myelodysplastic syndrome (MDS), a rare blood disorder that causes the bone marrow to form abnormal blood cells and can turn into a fast-growing cancer of the bone marrow.
Dutasteride, Capsule, 500g (Avodart) will help around 130,000 Australian men who experience lower urinary tract symptoms caused by prostate enlargement. This drug can reduce the likelihood of surgery being required by some sufferers.
Full details of these listing are available from the PBS website www.pbs.gov.au
